V Ann Stewart

Summary

Affiliation: Walter Reed Army Medical Center
Country: USA

Publications

  1. ncbi request reprint Plasmodium vivax under the microscope: the Aotus model
    V Ann Stewart
    Department of Immunology, Walter Reed Army Institute of Research, 503 Robert Grant Avenue, Silver Spring, MD 20910, USA
    Trends Parasitol 19:589-94. 2003
  2. doi request reprint Adenovirus 5 and 35 vectors expressing Plasmodium falciparum circumsporozoite surface protein elicit potent antigen-specific cellular IFN-gamma and antibody responses in mice
    Joseph P Shott
    Division of Malaria Vaccine Development, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA
    Vaccine 26:2818-23. 2008
  3. pmc Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone
    V Ann Stewart
    Division of Malaria Vaccine Development, Walter Reed Army Institute of Research, Silver Spring, MD, USA
    Infect Immun 75:2283-90. 2007
  4. ncbi request reprint Cutaneous delayed-type hypersensitivity (DTH) in a multi-formulation comparator trial of the anti-falciparum malaria vaccine candidate RTS,S in rhesus macaques
    V Ann Stewart
    Department of Immunology, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA
    Vaccine 24:6493-502. 2006
  5. ncbi request reprint Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A
    V Ann Stewart
    Department of Immunology, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, USA
    Vaccine 24:6483-92. 2006
  6. doi request reprint Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection
    James F Cummings
    Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA
    Vaccine 28:5135-44. 2010
  7. pmc Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A
    Michele D Spring
    United States Military Malaria Vaccine Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America
    PLoS ONE 4:e5254. 2009
  8. ncbi request reprint Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research
    Mark E Polhemus
    Walter Reed Army Institute of Research, Silver Spring, MD, United States
    Vaccine 25:4203-12. 2007
  9. doi request reprint Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection
    Kent E Kester
    Walter Reed Army Institute of Research, 503 Robert Grant Ave, Silver Spring, MD 20910, USA
    J Infect Dis 200:337-46. 2009
  10. ncbi request reprint Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research
    D Gray Heppner
    Walter Reed Army Institute of Research, Department of Immunology, 503 Robert Grant Avenue, Silver Spring, MD 20910, USA
    Vaccine 23:2243-50. 2005

Collaborators

Detail Information

Publications19

  1. ncbi request reprint Plasmodium vivax under the microscope: the Aotus model
    V Ann Stewart
    Department of Immunology, Walter Reed Army Institute of Research, 503 Robert Grant Avenue, Silver Spring, MD 20910, USA
    Trends Parasitol 19:589-94. 2003
  2. doi request reprint Adenovirus 5 and 35 vectors expressing Plasmodium falciparum circumsporozoite surface protein elicit potent antigen-specific cellular IFN-gamma and antibody responses in mice
    Joseph P Shott
    Division of Malaria Vaccine Development, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA
    Vaccine 26:2818-23. 2008
    ..Here we report that Ad5.CS, Ad35.CS, and RTS,S/AS01B, elicited both cellular and serologic CSP antigen-specific responses in mice. These adenoviral vectors induce strong malaria-specific immunity and warrant further evaluation...
  3. pmc Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone
    V Ann Stewart
    Division of Malaria Vaccine Development, Walter Reed Army Institute of Research, Silver Spring, MD, USA
    Infect Immun 75:2283-90. 2007
    ..The increased T-cell responses induced by the combination of Ad35.CS and RTS,S/AS01B are sustained for at least 6 months postvaccination and may translate to improved and more durable protection against P. falciparum infection in humans...
  4. ncbi request reprint Cutaneous delayed-type hypersensitivity (DTH) in a multi-formulation comparator trial of the anti-falciparum malaria vaccine candidate RTS,S in rhesus macaques
    V Ann Stewart
    Department of Immunology, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA
    Vaccine 24:6493-502. 2006
    ..To supplement in vitro immunogenicity assays, cutaneous delayed-type hypersensitivity (DTH) may be a useful indicator of functional, cell-mediated immunogenicity...
  5. ncbi request reprint Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A
    V Ann Stewart
    Department of Immunology, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, USA
    Vaccine 24:6483-92. 2006
    ..Pre-clinical studies are on-going to identify new RTS,S formulations with improved magnitude and duration of specific immunity...
  6. doi request reprint Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection
    James F Cummings
    Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA
    Vaccine 28:5135-44. 2010
    ....
  7. pmc Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A
    Michele D Spring
    United States Military Malaria Vaccine Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America
    PLoS ONE 4:e5254. 2009
    ....
  8. ncbi request reprint Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research
    Mark E Polhemus
    Walter Reed Army Institute of Research, Silver Spring, MD, United States
    Vaccine 25:4203-12. 2007
    ..1/AS02A in an endemic population in the Republic of Mali...
  9. doi request reprint Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection
    Kent E Kester
    Walter Reed Army Institute of Research, 503 Robert Grant Ave, Silver Spring, MD 20910, USA
    J Infect Dis 200:337-46. 2009
    ..To further increase the efficacy of malaria vaccine RTS,S/AS02A, we tested the RTS,S antigen formulated using the AS01B Adjuvant System (GlaxoSmithKline Biologicals)...
  10. ncbi request reprint Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research
    D Gray Heppner
    Walter Reed Army Institute of Research, Department of Immunology, 503 Robert Grant Avenue, Silver Spring, MD 20910, USA
    Vaccine 23:2243-50. 2005
    ..Recent safety, immunogenicity, and efficacy trials in the US and Africa are presented, as well as plans for the development of a multi-antigen vaccine...
  11. ncbi request reprint Characterization of a human reference standard for antibody to Plasmodium falciparum merozoite surface protein 1(42)
    In Kyu Yoon
    Division of Communicable Diseases and Immunology, Department of Immunology, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, USA
    Am J Trop Med Hyg 72:714-8. 2005
    ..3 microg/mL of MSP-1(42) antibody. This reference standard may be useful as a quantitative working standard for measuring MSP-1(42) antibody response in future vaccine clinical trials involving MSP-1...
  12. pmc Activation of innate immunity in healthy Macaca mulatta macaques by a single subcutaneous dose of GMP CpG 7909: safety data and interferon-inducible protein-10 kinetics for humans and macaques
    V Ann Stewart
    Walter Reed Army Institute of Research, Silver Spring, Maryland, USA
    Clin Vaccine Immunol 15:221-6. 2008
    ....
  13. ncbi request reprint Heterologous prime-boost immunization in rhesus macaques by two, optimally spaced particle-mediated epidermal deliveries of Plasmodium falciparum circumsporozoite protein-encoding DNA, followed by intramuscular RTS,S/AS02A
    Douglas S Walsh
    Department of Immunology and Medicine, US Army Medical Component, Armed Forces Research Institute of Medical Sciences AFRIMS, Bangkok, Thailand
    Vaccine 24:4167-78. 2006
    ..In field studies, RTS,S/AS02A reduced malaria infection, clinical episodes, and disease severity. Heterologous prime-boost immunization regimens, optimally spaced, might improve the protective immunity of RTS,S/AS02A...
  14. pmc Enzyme-linked immunosorbent assay for detection of Plasmodium falciparum histidine-rich protein 2 in blood, plasma, and serum
    Carolyne M Kifude
    Walter Reed Project Kenya Medical Research Institute, Kisumu, Kenya
    Clin Vaccine Immunol 15:1012-8. 2008
    ..We conclude that PfHRP2 ELISA using whole-blood and serum samples is a suitable adjunct to microscopy and could ultimately benefit malaria intervention trials...
  15. pmc Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trial
    Mahamadou A Thera
    Malaria Research and Training Center, University of Bamako, Bamako, Mali
    PLoS ONE 3:e1465. 2008
    ..The objective was to evaluate the safety, reactogenicity and immunogenicity of the AMA-1-based blood-stage malaria vaccine FMP2.1/AS02A in adults exposed to seasonal malaria...
  16. ncbi request reprint Malaria blood stage parasites activate human plasmacytoid dendritic cells and murine dendritic cells through a Toll-like receptor 9-dependent pathway
    Sathit Pichyangkul
    Department of Immunology and Medicine, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand
    J Immunol 172:4926-33. 2004
    ....
  17. ncbi request reprint Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya
    Jose A Stoute
    US Army Medical Research Unit and the Kenya Medical Research Institute, Nairobi, Kenya
    Vaccine 25:176-84. 2007
    ..16; P<0.001) and the Day 90 responses to MSP-1(42) (F1,335=16.69; P<0.001). The FMP1/AS02A vaccine is safe and immunogenic in adults and should progress to safety testing in children at greatest risk of malaria...
  18. doi request reprint Improved T cell responses to Plasmodium falciparum circumsporozoite protein in mice and monkeys induced by a novel formulation of RTS,S vaccine antigen
    Pascal Mettens
    GlaxoSmithKline Biologicals, Rixensart, Belgium
    Vaccine 26:1072-82. 2008
    ..Our data provides clear evidence that combining RTS,S antigen with a potent adjuvant induces strong humoral and cellular responses in vivo...
  19. doi request reprint Status of malaria vaccine R&D in 2007. Malaria Vaccines for the World 2007, September 17-19th, 2007, London, UK
    Denise L Doolan
    The Queensland Institute of Medical Research, The Bancroft Centre, 300 Herston Road, PO Royal Brisbane Hospital, Brisbane QLD 4029, Australia
    Expert Rev Vaccines 6:903-5. 2007